Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma Clinical Trial

Official title:

A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05963347
• Other study ID #: DZ2022J0003
• Status: Recruiting
• Phase: Phase 2
• Start date: August 3, 2023
• Est. completion date: July 31, 2026

Study information

• Verified date: August 2023
• Source: Henan Cancer Hospital
• Contact: Keshu Zhou, Dr.
• Phone: +86 (0371) 65587513
• Email: drzhouks77[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: July 31, 2026
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants must sign an informed consent form prior to trial-specific procedures, sampling, and analysis.

2. Participants must be at least 18 years of age (inclusive) at the time of signing the informed consent form.

3. The participant has an ECOG performance status of 0 to 2 and has not deteriorated in the past 2 weeks.

4. Life expectancy = 3 months.

5. Histologically confirmed diagnosis of PTCL and no prior systemic anti-lymphoma therapy; and assessed by a local pathologist according to the 2016 revised World Health Organization Classification of Lymphoid Tumors (Swerdlow SH et al., 2017) as the following subtypes:

• peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)

• angioimmunoblastic T cell lymphoma (AITL)

• follicular T-cell lymphoma (FTCL)

• nodular PTCL with follicular helper T-cell phenotype (nodular PTCL with TFH phenotype)

• ALK- anaplastic large cell lymphoma (ALK- ALCL)

• ALK+ anaplastic large cell lymphoma (ALK + ALCL)

• enteropathy-associated T-cell lymphoma (EATL)

• monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)

• hepatosplenic T-cell lymphoma (HSTCL)

• subcutaneous panniculitis-like T-cell lymphoma (SPTCL)

6. Adequate bone marrow reserve and organ system function reserve

7. Left ventricular ejection fraction (LVEF) = 50% as assessed by ECHO.

8. Participants should be able and willing to comply with the study protocol requirement.

9. Adequate birth control measures should be taken during study treatment and the corresponding washout period.

Exclusion Criteria:

1. Received any of the following interventions:

• Prior therapy for PTCL prior to enrollment, except short-term corticosteroids (duration = 7 days, equivalent prednisone dose = 15 mg/day).

• Prior radiation therapy for PTCL except local therapy for individual areas.

• Currently receiving other systemic antineoplastic or investigational therapy.

• Participants who have received more than 200 mg/m2 doxorubicin or other equivalent doses of anthracycline/anthraquinone (e.g., epirubicin, daunorubicin, mitoxantrone, etc.) cumulatively.

• Major surgical procedures (excluding routine lymphoma care programs such as vascular access placement, biopsy, etc.) or significant trauma within 4 weeks prior to the first dose of study treatment, or anticipation of the need for major surgery during the study.

• Prior treatment with JAK or STAT3 inhibitors following diagnosis of PTCL.

• Live vaccine within 28 days prior to enrollment.

• Participants currently receiving (or unable to discontinue for at least 1 week prior to first dose) vitamin K antagonists, antiplatelets, or anticoagulants.

• Participants currently receiving (or unable to discontinue for at least 1 week prior to receiving the first dose) medications or herbal supplements known to be highly potent inhibitors or inducers of CYP3A or sensitive substrates of BCRP or P-gp with a narrow therapeutic index (see Section 6.8).

2. Participants with clinical manifestations or imaging findings suggesting central nervous system or leptomeningeal lymphoma.

3. Participants with severe lung dysfunction, pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any prior history of clinically active interstitial lung disease.

4. Participants with a condition that requires treatment with immunosuppressants, biologics, or nonsteroidal anti-inflammatory drugs (NSAIDs).

5. Participants with active infections

6. Participants with significant cardiac disorder

7. Other malignancies within 3 years before enrollment. However, malignancies, such as uterine and cervical carcinoma in situ, basal or squamous cell carcinoma, and non-melanotic skin cancer, which have been clinically cured after evaluation, may be considered for inclusion after evaluation.

8. Refractory nausea or vomiting that cannot be controlled by supportive therapy, chronic gastrointestinal disease, inability to swallow pharmaceutical agents or previous major bowel resection may affect the adequate absorption of golidocitinib.

9. Female participants who are lactating.

10. Participants with a history of hypersensitivity against the active ingredients or excipients of golidocitinib or against similar chemical structures or drugs of the same class. Contraindication to any agent in the CHOP chemotherapy regimen.

11. Participants with any severe or poorly controlled systemic disease, such as poorly controlled hypertension or active bleeding constitution, as judged by the investigator or other evidence.

12. Participants with an intercurrent illness that, in the opinion of the investigator, may jeopardize compliance with the protocol, including any significant medical condition, laboratory abnormality, or psychiatric disorder.

13. Participants with psychological, familial, social, or geographical conditions that preclude compliance with the program. Any condition that would confound the ability to interpret study data.

14. Participating in study planning and implementation.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T Cell Lymphoma

Intervention

Drug:
• Golidocitinib
Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
• CHOP Regimen
CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	TEAE, lab test	From first dose till 28 days post the last dose
Secondary	Complete Response Rate	Complete response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria	From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)
Secondary	Objective Response Rate	Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria.	From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)
Secondary	Progression Free Survival	Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria.	From date of enrollment (first dose) until documented disease progression or death of any reason (up 2 year)
Secondary	Duration of Response	Duration of response assessed by investigator per Lugano 2014 criteria	from first documented response till disease progression or death of any reason (up to 2 years)